Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3b study of dabrafenib + trametinib adjuvant therapy in resected stage III BRAF V600-mutant melanoma evaluating the Plus pyrexia-management algorithm
MOH_2018-08-13_002512Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dabrafenib + trametinib and trametinib in melanoma, sponsored by Novartis. Primary endpoint: Pyrexia-related outcomes. Started Aug 2018; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on MOH_2018-08-13_002512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-08-13_002512.